论文部分内容阅读
应用漂浮导管监测前列腺素Ｅ１（ＰＧＥ１）对１１例以二尖瓣狭窄为主的风湿性心脏病合并肺动脉高压患者的体循环和肺循环的血液动力学作用。先以ＰＧＥ１２０ｎｇ·ｋｇ（－１）／ｍｉｎ静脉滴注１０分钟，再按患者情况每５～１０分钟增加５～１０ｎｇ·ｋｇ（－１）／ｍｉｎ。初剂量１０分钟时显著降低了平均肺动脉压（ＭＰＡＰ，Ｐ＜０．０１）、肺毛细血管楔压（ＰＣＷＰ，Ｐ＜０．０１）和右房压（ＲＡＰ，Ｐ＜０．０５）。剂量达３０．６±５．１ｎｇ·ｋｇ（－１）／ｍｉｎ维持１０及２０分钟时，ＭＰＡＰ、ＰＣＷＰ和ＲＡＰ等参数变化更显著；总外周阻力和肺血管阻力均显著降低（Ｐ＜０．０１），心脏指数显著增加（Ｐ＜０．０５），血压和心率的变化无显著性意义（Ｐ＞０．０５）。用药后，本组患者血液动力学异常基本被纠正，副作用轻微。提示ＰＧＥ１对风湿性心脏病二尖瓣狭窄为主的肺动脉高压患者有良好血液动力学效应。
Floating catheter was used to monitor the hemodynamic effects of prostaglandin E1 (PGE1) on systemic and pulmonary circulation in 11 patients with mitral stenosis predominantly with rheumatic heart disease and pulmonary hypertension. The first infusion of PGE120ng · kg (-1) / min intravenous infusion for 10 minutes, according to the patient every 5 to 10 minutes to increase 5 ~ 10ng · kg (-1) / min. Mean pulmonary artery pressure (MPAP, P <0.01), pulmonary capillary wedge pressure (PCWP, P <0.01), and right atrial pressure (RAP, P <0.05) were significantly reduced at the initial dose of 10 min. The parameters of MPAP, PCWP and RAP changed more significantly when the dosage was 30.6 ± 5.1ng · kg -1 / min for 10 and 20 minutes. The total peripheral resistance and pulmonary vascular resistance were significantly decreased (P <0. 01), cardiac index increased significantly (P <0.05), and blood pressure and heart rate had no significant difference (P> 0.05). After treatment, this group of patients with hemodynamic abnormalities were basically corrected, minor side effects. Tip PGE1 rheumatic mitral stenosis predominant pulmonary hypertension patients have a good hemodynamic effect.